Latest News
- Min. Nadda Unveils ?13,000-Crore Bio-Pharma SHAKTI and Chemical Parks Push to Expand India’s Global Chemicals and Biologics Footprint
- Aurobindo Pharma Subsidiary Launches Generic Cancer Drug in US, Expands Oncology Portfolio in Global Generics Market
- KIMS Hospitals Introduces Adaptive Deep Brain Stimulation in India for Advanced Parkinson’s Treatment
Sun Pharma Unveils Fexuclue: A Breakthrough Treatment for Erosive Esophagitis in India
The newly introduced medication belongs to the potassium-competitive acid blocker (PCAB) class, a novel category of acid-suppressing drugs. Approved for adult patients across all grades of Erosive Esophagitis, Fexuclue aims to address persistent treatment gaps and improve patient outcomes.
- By Newsdesk
- New Delhi
- Apr 07, 2025
Sun Pharmaceutical Industries has announced the launch of Fexuclue (Fexuprazan 40 mg tablets), a cutting-edge therapy for the treatment of Erosive Esophagitis (EE), marking a significant advancement in gastrointestinal care in India.
The newly introduced medication belongs to the potassium-competitive acid blocker (PCAB) class, a novel category of acid-suppressing drugs. Approved for adult patients across all grades of Erosive Esophagitis, Fexuclue aims to address persistent treatment gaps and improve patient outcomes.
Sun Pharma has secured the rights to manufacture and market Fexuprazan in India through a strategic agreement with Daewoong Pharmaceutical, a South Korea-based pharmaceutical company. The partnership includes upfront and milestone-based financial arrangements, as well as royalty payments to Daewoong.
“Erosive Esophagitis is a debilitating condition that severely impacts quality of life. While current therapies exist, there is a clear unmet need for more effective solutions. Fexuclue presents a best-in-class option to bridge this gap,” said Kirti Ganorkar, CEO – India Business at Sun Pharma.
The drug’s efficacy was demonstrated in a rigorous Phase 3 clinical trial conducted in India. This double-blind, double-dummy, comparative study confirmed the healing of EE through endoscopic evaluation. Impressively, over 95% of patients experienced complete healing within eight weeks, meeting the study’s primary endpoint.
Despite the promising development, shares of Sun Pharma were trading 2.97% lower at ₹1,658.60 on the BSE at the time of the announcement.
Fexuclue is expected to offer a much-needed alternative for EE patients who have had limited success with existing therapies, potentially reshaping the standard of care in gastroenterology.